MedPath

AB-201

Generic Name
AB-201
Drug Type
Biotech

Overview

AB-201 is a CAR-NK cell therapy targeted against HER2. It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

Background

AB-201 is a CAR-NK cell therapy targeted against HER2. It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath